A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) in Combination with Guideline-Based Therapy in Patients with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B)

15074MKC-CI-002Open (affiliates only)A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) in Combination with Guideline-Based Therapy in Patients with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B)NCT06418711IndustrialAdultTreatmentII/IIIOtherO'Donnell, AnneGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Pulmonary; GUMC PFS2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>